China Feihe’s Valuation After Indonesian Formula Approval And Weaker 2025 Earnings

Simply Wall St.04-02

AdvertisementWhy the Indonesian approval matters for China Feihe The latest move by China Feihe (SEHK:6186) is approval for its AceKid Activegro infant formula series to enter Indonesia, coming soon ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2624871526?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/5122000-choice1-main-header/1585186630654","is_english":true,"pubTime":"2026-04-02 08:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2624871526","market":"nz","top_or_hot":-1,"title":"China Feihe’s Valuation After Indonesian Formula Approval And Weaker 2025 Earnings","media":"Simply Wall St.","content":"<div>\n<p>AdvertisementWhy the Indonesian approval matters for China Feihe The latest move by China Feihe (SEHK:6186) is approval for its AceKid Activegro infant formula series to enter Indonesia, coming soon ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/food-beverage-tobacco/hkg-6186/china-feihe-shares/news/china-feihes-valuation-after-indonesian-formula-approval-and\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>China Feihe’s Valuation After Indonesian Formula Approval And Weaker 2025 Earnings</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChina Feihe’s Valuation After Indonesian Formula Approval And Weaker 2025 Earnings\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-04-02 08:31 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/hk/food-beverage-tobacco/hkg-6186/china-feihe-shares/news/china-feihes-valuation-after-indonesian-formula-approval-and><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AdvertisementWhy the Indonesian approval matters for China Feihe The latest move by China Feihe (SEHK:6186) is approval for its AceKid Activegro infant formula series to enter Indonesia, coming soon ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/food-beverage-tobacco/hkg-6186/china-feihe-shares/news/china-feihes-valuation-after-indonesian-formula-approval-and\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1553","symbol_name":"奶制品股","start_time":0,"source_url":"https://simplywall.st/stocks/hk/food-beverage-tobacco/hkg-6186/china-feihe-shares/news/china-feihes-valuation-after-indonesian-formula-approval-and","article_id":"2624871526","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/5122000-choice1-main-header/1585186630654"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/food-beverage-tobacco/hkg-6186/china-feihe-shares/news/china-feihes-valuation-after-indonesian-formula-approval-and","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2624871526","pubTimestamp":1775089892,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Why the Indonesian approval matters for China Feihe\nThe latest move by China Feihe (SEHK:6186) is approval for its AceKid Activegro infant formula series to enter Indonesia, coming soon after full year 2025 results that showed lower sales and net income versus the prior year.\nThis combination of fresh overseas expansion and softer annual earnings gives you two key angles to watch: how effectively Feihe can build a presence in Southeast Asian markets, and how that interacts with its current...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1553":"奶制品股","BK1589":"北水核心资产","BK1597":"三胎概念","06186":"中国飞鹤","DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","BK1500":"做空集合股","BK1237":"包装食品与肉类"},"translate_title":"中国飞鹤在印度尼西亚配方获得批准和2025年盈利疲软后的估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DCF":1,"06186":0.9},"content_text":"AdvertisementWhy the Indonesian approval matters for China Feihe The latest move by China Feihe (SEHK:6186) is approval for its AceKid Activegro infant formula series to enter Indonesia, coming soon after full year 2025 results that showed lower sales and net income versus the prior year. This combination of fresh overseas expansion and softer annual earnings gives you two key angles to watch: how effectively Feihe can build a presence in Southeast Asian markets, and how that interacts with its current profitability profile. See our latest analysis for China Feihe. Despite the Indonesia and Philippines expansion, the share price has been under pressure. A 90 day share price return of 13.79% and a 1 year total shareholder return decline of 35.77% point to fading momentum and ongoing investor caution. If this mix of overseas growth plans and weaker returns has you reassessing your watchlist, it could be a good moment to broaden your search and check out 96 top founder-led companies With earnings under pressure, a multi year total return decline and shares trading below some valuation estimates, you have to ask: is China Feihe now being undervalued, or is the market already pricing in any future growth? Price-to-Earnings of 13.9x: Is it justified? On a P/E of 13.9x, China Feihe is priced below several reference points, which hints at a market that is cautious despite the current earnings profile. The P/E multiple compares the share price to earnings per share. It gives a quick read on how much investors are paying for each unit of profit. For a consumer staples name like Feihe, this is a commonly watched yardstick because earnings tend to be a central anchor for how investors think about valuation. Here, the company is described as trading at good value versus peers and the broader Hong Kong Food industry. The 13.9x P/E sits below both the peer average of 17.3x and the industry average of 14.1x. It also screens as good value versus an estimated fair P/E of 16.1x, which is a level the market could move toward if sentiment around Feihe’s earnings quality and growth outlook were to converge with that reference point. Explore the SWS fair ratio for China Feihe Result: Price-to-Earnings of 13.9x (UNDERVALUED) However, the decline in long run total return, recent share price weakness, and reliance on Mainland China revenue could all keep pressure on how the stock is valued. Find out about the key risks to this China Feihe narrative. Another angle: the SWS DCF fair value While the 13.9x P/E hints at good value, the SWS DCF model goes further, suggesting China Feihe is trading at about a 56% discount to an estimated fair value of HK$7.96 per share. That is a wide gap, so is the market seeing risks that the model does not? Look into how the SWS DCF model arrives at its fair value. 6186 Discounted Cash Flow as at Apr 2026Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out China Feihe for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 250 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity. Next Steps If this mix of discounted valuation and overseas expansion leaves you unsure, now is the time to look at the data yourself and weigh both sides, starting with the 4 key rewards and 2 important warning signs. Looking for more investment ideas? If you stop at one stock, you could miss better fits for your goals, so use the tools at hand and give yourself more options.  Spot potential value opportunities early by scanning 250 high quality undervalued stocks that pair solid fundamentals with attractive pricing. Build a more resilient watchlist by focusing on 273 resilient stocks with low risk scores that score well on financial strength and volatility checks. Hunt for future standouts before they attract broad attention by running the screener containing 590 high quality undiscovered gems and seeing what fits your criteria.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2624871526","isCrawlerRequest":true}